Skip to main content

Table 3 Survival characteristics for standard and high risk IMWG groups sub-stratified with CAGP model

From: Centrosome associated genes pattern for risk sub-stratification in multiple myeloma

Stratification group

N

HR (95 % CI)

Survival median (months)

3-years outcome (%)

p value (log-rank)

Overall survival

 Low risk CAGP

66

 

38.8

53.8

<0.00799

 High risk CAGP

84

1.8 (1.16; 2.80)

22.1

25.1

 IMWG standard risk

41

 

22.8

32.1

<0.1371

 IMWG high risk

28

1.6 (0.86; 2.91)

15.8

23.5

 IMWG standard risk/low risk CAGP

18

 

29.2

42.9

<0.4532

 IMWG standard risk/high risk CAGP

23

1.4 (0.59; 3.25)

22.8

27.4

 IMWG high risk/low risk CAGP

14

 

16.6

49.9

<0.02836

 IMWG high risk/high risk CAGP

14

2.8 (1.07; 7.45)

11.5

8.2

Time to progression

 Low risk CAGP

66

 

13.6

11.5

<0.1939

 High risk CAGP

84

1.3 (0.88; 1.88)

13.0

8.7

 IMWG standard risk

41

 

13.2

6.9

<0.7824

 IMWG high risk

28

1.1 (0.62; 1.89)

12.0

0

 IMWG Standard risk/low risk CAGP

18

 

12.3

0

<0.9978

 IMWG standard risk/high risk CAGP

23

1 (0.48; 2.07)

14.5

9.6

 IMWG high risk/low risk CAGP

14

 

17.7

0

<0.05469

 IMWG high risk/high risk CAGP

14

2.3 (0.96; 5.55)

8.0

0

Progression free survival

 Low risk CAGP

66

 

12.6

10.8

<0.06232

 High risk CAGP

84

1.4 (0.98; 2.03)

10.2

5.6

 IMWG standard risk

41

 

13.2

6.3

<0.8121

 IMWG high risk

28

1.1 (0.62; 1.84)

11.4

0

 IMWG standard risk/low risk CAGP

18

 

12.3

0

<0.9395

 IMWG standard Risk/high risk CAGP

23

1 (0.48; 1.97)

13.9

9.1

 IMWG high risk/low risk CAGP

14

 

17.7

0

<0.0325

 IMWG high risk/high risk CAGP

14

2.5 (1.05; 5.89)

7.7

0

  1. “Low risk CAGP” group includes patients with “Low expressed” centrosome associated gene pattern. “High risk CAGP” group includes patients with united “High and medium expressed” centrosome associated gene pattern. “IMWG standard risk” group includes patients with ISS III and no adverse FISH or ISS I and t(4;14)/17p13 del; “IMWG high risk” group includes patients with ISS II/III and t(4;14)/17p13 del